Find out more about how this website uses cookies to enhance your browsing experience.
Accept Cookies
Radiation therapy is getting more precise, enabled by technologies that make it easier to kill tumors while sparing their surrounding tissues. Some newer therapies are even given intravenously rather than by machines, and that they deliver radiation particles onto the neoplastic cell itself. one among these new therapies a kind of bomb targeted at malignant cells is now generating promising data for men with the foremost aggressive prostatic adenocarcinoma.
In early June, investigators reported results from a phase 3 clinical test showing that among men who received the experimental treatment, there was nearly a 40% reduction in deaths throughout the study, compared to men who didn't.
The treatment is named lutetium-177-PSMA-617, or LuPSMA, and it's two components: a compound that targets a neoplastic cell protein called prostate-specific membrane antigen, or PSMA, and a radioactive particle that destroys the cells. Healthy prostate cells don't contain PSMA, or do at very low levels. and a few men with prostatic adenocarcinoma have more of the protein than others. Doctors can detect the protein by employing a specialized imaging scan.
To qualify for enrollment within the study, called the VISION trial, men had to be PSMA-positive. In all, 831 men were split into two groups: one group got the experimental treatment plus standard of care, while men within the control group got standard of care only. All the lads had metastatic castration-resistant prostatic adenocarcinoma, meaning that the disease was spreading within the body and not responding to drugs that suppress testosterone (which fuels growing tumors).
Results after 21 months showed that cancer progression was delayed for extended among the LuPSMA-treated men: 8.7 months on average versus 3.4 months among the controls. The treatment was also related to better overall survival: 15.3 months versus 11.3 months.
The VISION study comes on the heels of an earlier phase 2 study (known as TheraP) that compared LuPSMA to chemotherapy during a population of 200 men. During that study, investigators monitored how the treatment affected prostate-specific antigen (PSA) levels, which usually increase if cancer starts growing. In two-thirds of the LuPSMA-treated men, PSA levels fell by 50% or more. And as within the VISION trial, the experimental treatment was better at delaying cancer progression, which was confirmed with traditional imaging tests.
Dr. Thomas Hope, a radiologist, and professor at the University of California, San Francisco, has been closely following this research. He says that therapy is arguably the higher study, since investigators therein case compared LuPSMA to chemotherapy, whereas the standard of care within the VISION study excluded chemotherapy, immunotherapy, and other agents that doctors would otherwise try. In other words, Hope says, the VISION study compared LuPSMA to "nothing," which might ordinarily never happen. "So, the VISION trial doesn't assist you the maximum amount in terms of deciding which treatment to settle on," he says.
LuPSMA was generally well-tolerated, but it also had side effects including fatigue, nausea, kidney problems, and bone marrow suppression. Dr. Hope says more research is required to work out how and when to use the drug, "since if you've got an 8 to10 year expected lifespan, these side effects are often problematic."
If it's approved by the FDA, LuPSMA is going to be the primary PSMA-targeted drug for prostatic adenocarcinoma to succeed in the market.
"The addition of both diagnostic and treatment advances represents true milestones in improving the outcomes of men with resistant prostatic adenocarcinoma. the present studies are particularly important because the criteria for using the new therapeutic radioactive substance is provided only to men who show that their cancers express the target of the new treatment. this is often increasing our precision in both selecting treatments and administering them to patients who have the best likelihood of deriving benefit. Physicians who treat prostatic adenocarcinoma patients are excited by these advances, and appearance forward to the broader availability of both novel diagnostic and targeted treatment modalities.”
© 2024. All rights reserved.
Radiation therapy is getting more precise, enabled by technologies that make it easier to kill tumors while sparing their surrounding tissues. Some newer therapies are even given intravenously rather than by machines, and that they deliver radiation particles onto the neoplastic cell itself. one among these new therapies a kind of bomb targeted at malignant cells is now generating promising data for men with the foremost aggressive prostatic adenocarcinoma.
In early June, investigators reported results from a phase 3 clinical test showing that among men who received the experimental treatment, there was nearly a 40% reduction in deaths throughout the study, compared to men who didn't.
The treatment is named lutetium-177-PSMA-617, or LuPSMA, and it's two components: a compound that targets a neoplastic cell protein called prostate-specific membrane antigen, or PSMA, and a radioactive particle that destroys the cells. Healthy prostate cells don't contain PSMA, or do at very low levels. and a few men with prostatic adenocarcinoma have more of the protein than others. Doctors can detect the protein by employing a specialized imaging scan.
To qualify for enrollment within the study, called the VISION trial, men had to be PSMA-positive. In all, 831 men were split into two groups: one group got the experimental treatment plus standard of care, while men within the control group got standard of care only. All the lads had metastatic castration-resistant prostatic adenocarcinoma, meaning that the disease was spreading within the body and not responding to drugs that suppress testosterone (which fuels growing tumors).
Results after 21 months showed that cancer progression was delayed for extended among the LuPSMA-treated men: 8.7 months on average versus 3.4 months among the controls. The treatment was also related to better overall survival: 15.3 months versus 11.3 months.
The VISION study comes on the heels of an earlier phase 2 study (known as TheraP) that compared LuPSMA to chemotherapy during a population of 200 men. During that study, investigators monitored how the treatment affected prostate-specific antigen (PSA) levels, which usually increase if cancer starts growing. In two-thirds of the LuPSMA-treated men, PSA levels fell by 50% or more. And as within the VISION trial, the experimental treatment was better at delaying cancer progression, which was confirmed with traditional imaging tests.
Dr. Thomas Hope, a radiologist, and professor at the University of California, San Francisco, has been closely following this research. He says that therapy is arguably the higher study, since investigators therein case compared LuPSMA to chemotherapy, whereas the standard of care within the VISION study excluded chemotherapy, immunotherapy, and other agents that doctors would otherwise try. In other words, Hope says, the VISION study compared LuPSMA to "nothing," which might ordinarily never happen. "So, the VISION trial doesn't assist you the maximum amount in terms of deciding which treatment to settle on," he says.
LuPSMA was generally well-tolerated, but it also had side effects including fatigue, nausea, kidney problems, and bone marrow suppression. Dr. Hope says more research is required to work out how and when to use the drug, "since if you've got an 8 to10 year expected lifespan, these side effects are often problematic."
If it's approved by the FDA, LuPSMA is going to be the primary PSMA-targeted drug for prostatic adenocarcinoma to succeed in the market.
"The addition of both diagnostic and treatment advances represents true milestones in improving the outcomes of men with resistant prostatic adenocarcinoma. the present studies are particularly important because the criteria for using the new therapeutic radioactive substance is provided only to men who show that their cancers express the target of the new treatment. this is often increasing our precision in both selecting treatments and administering them to patients who have the best likelihood of deriving benefit. Physicians who treat prostatic adenocarcinoma patients are excited by these advances, and appearance forward to the broader availability of both novel diagnostic and targeted treatment modalities.”
© 2024. All rights reserved.
Our aim is to offer better technology to healthcare providers who in turn can provide better care for the health seekers.
Just go to the S10.Clinic website and click on the "Book appointment" button on the homepage of the website/app, select a specialty and find the doctor of your choice. Once you select a doctor, you can click on the "Consult Online" button to select your preferred date and time.
Once you select the date and time all you have to do is sign up / login to the platform and make the payment online using your credit / debit card on the Razor pay or CC Avenue gateway. Then, you will receive the consultation link via sms / email.
Our online consultation platform is optimized for the following browsers: Google Chrome and Safari. Please ensure you are free 10 minutes prior to your appointment.
All you have to do is find a well light and quiet place with good internet connectivity, preferably a place with Wi-Fi access. Switch on your microphone (for laptop / mobile and allow browser to access it).
Please note: If you are not able to open the link please delete your browser history and cache files of your browser and try again.
This may happen due to poor internet connectivity. In such cases, please check your internet connection and if the issue persists, please reach out to us at onlineconsulting@s10.clinic with the screenshot of the error and we will get this checked from our end. You can also call us at 044-40510510.
Please note: Please ensure you have given access to your audio and video to your browser in the settings panel.
You will receive an email after the online consultation with the following - Provisional diagnosis, visit notes, prescription and follow up.
Yes. The prescription generated during the online consultation is as good as a physical prescription and will be valid for 6 months from the date of issue (as per government regulations).
You will be able to speak and interact with the doctor only for the time he has specified.
Yes. The e-prescription will be valid for offline pharmacies as well.
Safety of your data is our top priority. We have multi-level security checks, multiple data backups, and stringent policies in place to ensure your data remains safe and secure. Additionally, we are a HIPAA compliant company and we take data privacy and security very seriously. All data on S10.Clinic is secured with 256-bit encryption.
All the patients who use the S10.Clinic platform will be called and verified by our support squad before their consultation with the doctors.
You don't have to worry about it. In that case an automatic refund is initiated from our end, and it will reflect in your bank account within 6-7 business days.
Or you can reach out to us at 044-40510510 or onlineconsulting@s10.clinic and we will be happy to help you.
Don't worry if you've missed the online call with the, you can easily reschedule the call with your preferred doctor 10 minutes prior to any consultation. All you have to do is click on the "Reschedule" option in the appointment email.
Or you can reach out to us at 044-40510510 and we can book the same for you.
Please note: If you do not show up or miss an appointment after your appointment time, you won't be able to reschedule it.
You can reschedule any appointment you make 10 minutes before the consultation free of cost. If you want to reschedule any appointment after the consultation time has started you will have to book a new appointment with your preferred doctor. No refund will be offered in such cases.
After the online consultation you will receive a feedback form where you can rate your experience and tell us what went well, what we need to work on. We take your feedback very seriously and this helps us to improve our app and our services.
We're always there for you! You can reach out to our Support Squad at 044-40510510 or send us an email at onlineconsulting@s10.clinic. You can also dm us on Facebook we will be happy to assist you.
Comments